10:41 AM EDT, 07/16/2025 (MT Newswires) -- Revelation Biosciences ( REVB ) said Wednesday it completed dosing for an escalating-dose phase 1b trial of intravenously-administered Gemini in people with stage 3 and 4 chronic kidney disease.

The company said that, as planned, five groups were enrolled at three clinics in the US, and trial data sets are expected in Q3.

Revelation shares were up over 6% in recent trading.

Price: 3.06, Change: +0.19, Percent Change: +6.62